These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1050 related items for PubMed ID: 10604953

  • 1. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
    Li P, Fukuhara M, Diz DI, Ferrario CM, Brosnihan KB.
    J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
    [Abstract] [Full Text] [Related]

  • 2. Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats.
    Li P, Ferrario CM, Brosnihan KB.
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):198-205. PubMed ID: 9700980
    [Abstract] [Full Text] [Related]

  • 3. Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries.
    Li P, Ferrario CM, Brosnihan KB.
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1065-70. PubMed ID: 9190837
    [Abstract] [Full Text] [Related]

  • 4. The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo.
    Fukuhara M, Neves LA, Li P, Diz DI, Ferrario CM, Brosnihan KB.
    J Hypertens; 2001 Mar; 19(3 Pt 2):561-6. PubMed ID: 11327630
    [Abstract] [Full Text] [Related]

  • 5. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
    Montón M, Jiménez A, Núñez A, López-Blaya A, Farré J, Gómez J, Zalba LR, Sánchez de Miguel L, Casado S, López-Farré A.
    J Cardiovasc Pharmacol; 2000 Jun; 35(6):906-13. PubMed ID: 10836725
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
    Greenberg SS, Johns A, Kleha J, Xie J, Wang Y, Bianchi J, Conley K.
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950
    [Abstract] [Full Text] [Related]

  • 8. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release.
    Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T.
    Hypertension; 2002 Oct; 40(4):521-7. PubMed ID: 12364357
    [Abstract] [Full Text] [Related]

  • 9. AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II.
    Cediel E, de Las Heras N, Sanz-Rosa D, Velasco O, Cachofeiro V, Lahera V.
    Kidney Int Suppl; 2005 Jan; (93):S3-9. PubMed ID: 15613065
    [Abstract] [Full Text] [Related]

  • 10. Heterogeneity of prostaglandin H2/thromboxane A2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet aggregation.
    Furci L, Fitzgerald DJ, Fitzgerald GA.
    J Pharmacol Exp Ther; 1991 Jul 01; 258(1):74-81. PubMed ID: 1830100
    [Abstract] [Full Text] [Related]

  • 11. Effects of the new thromboxane A2 antagonist vapiprost on isolated canine blood vessels.
    Matsuzaki T, Noguchi K, Nakasone J, Uezu K, Higuchi M, Sakanashi M.
    Arzneimittelforschung; 1992 Nov 01; 42(11):1318-22. PubMed ID: 1492844
    [Abstract] [Full Text] [Related]

  • 12. Antagonistic effects of losartan on thromboxane A2-receptors in human isolated gastroepiploic artery and saphenous vein.
    Tripodi F, Stanke-Labesque F, Devillier P, Chavanon O, Sessa C, Bessard G.
    J Cardiovasc Pharmacol; 1999 Nov 01; 34(5):734-40. PubMed ID: 10547091
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Angiotensin II AT(1) receptor antagonists and platelet activation.
    López-Farré A, Sánchez de Miguel L, Montón M, Jiménez A, Lopez-Bloya A, Gómez J, Núñez A, Rico L, Casado S.
    Nephrol Dial Transplant; 2001 Nov 01; 16 Suppl 1():45-9. PubMed ID: 11369820
    [Abstract] [Full Text] [Related]

  • 15. Effects of U46619 on contractions to 5-HT, sumatriptan and methysergide in canine coronary artery and saphenous vein in vitro.
    Kemp BK, Cocks TM.
    Br J Pharmacol; 1995 Oct 01; 116(4):2183-90. PubMed ID: 8564247
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of contractile responses to 5-hydroxytryptamine and sumatriptan in human isolated coronary artery: synergy with the thromboxane A2-receptor agonist, U46619.
    Cocks TM, Kemp BK, Pruneau D, Angus JA.
    Br J Pharmacol; 1993 Sep 01; 110(1):360-8. PubMed ID: 8220898
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of vasoconstriction by the thromboxane A2 antagonist GR32191B in the human radial artery.
    He GW, Yang CQ.
    Br J Clin Pharmacol; 1999 Aug 01; 48(2):207-15. PubMed ID: 10417498
    [Abstract] [Full Text] [Related]

  • 20. Platelet-induced vasomotion of isolated canine coronary artery in the presence of halothane or isoflurane.
    Blaise GA, Parent M, Laurin S, Omri A, Reader TA, Moutquin JM.
    J Cardiothorac Vasc Anesth; 1994 Apr 01; 8(2):175-81. PubMed ID: 8204810
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.